Top

Published in:

01-03-2004 | Review

Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy

Authors: Constantin N. Baxevanis, Panagiota A. Sotiropoulou, Nectaria N. Sotiriadou, Michael Papamichail

Published in: Cancer Immunology, Immunotherapy | Issue 3/2004

Abstract

HER-2/neu (also known as HER2 or c-erb-B2) is a 185-kDa protein receptor with tyrosine kinase activity and extensive homology to the epidermal growth factor (EGF) receptor. HER-2/neu is expressed in many epithelial tumors and known to be overexpressed in approximately 20–25% of all ovarian and breast cancers, 35–45% of all pancreatic adenocarcinomas, and up to 90% of colorectal carcinomas. HER-2/neu overexpression represents a marker of poor prognosis. HER-2/neu-positive tumor cells are potentially good targets for tumor-reactive cytotoxic T lymphocytes which have been utilized in immunotherapeutic trials. In addition, the “humanized” monoclonal antibody Herceptin has been tested in several clinical trials and proved to be an effective adjuvant therapy for HER-2/neu-positive breast and ovarian cancers. Vaccinations aiming at generating T-cell responses are being examined in both experimental and clinical trials. Natural immunity at the level of T and B cells has been observed in patients with HER-2/neu-positive tumors confirming the immunogenicity of HER-2/neu and encouraging vaccination trials with HER-2 protein–derived subunits or synthetic peptides. This review summarizes recent data from patients with various types of HER-2/neu–overexpressing cancers carrying different HLA alleles and exhibiting preexistent immunity to HER-2/neu–derived synthetic peptides. It also discusses potential advantages of the various vaccination approaches to immunotherapy targeting the HER-2/neu molecule.

Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644PubMed

Akiyama T, Saito T, Ogawara H, Toyoshima K, Yamamoto T (1988) Tumor promoter and epidermal growth factor stimulate phosphorylation of the c-erb-B2 gene product in MKN-7 human adenocarcinoma cells. Mol Cell Biol 8:1019PubMed

Alroy I, Yarden Y (1977) The ErbB signalling network, in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410:83CrossRef

Altenschmidt U, Klundt E, Grower B (1997) Adoptive transfer of in vitro-targeted, activated lymphocytes results in total tumor regression. J.Immunol. 159:5509

Anderson BW, Kudelka AD, Honda T, Pollack MS Gershenson DM, Gillogly MA, Murray JL, Ioannides CG (2000) Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides. Cancer Immunol Immunother 49:459CrossRefPubMed

Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M (2000) Tumor-specific CD4⁺ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 164:3902PubMed

Baxevanis CN, Gritzapis AD, Tsitsilonis OE, Katsoulas HL, Papamichail M (2002) HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3⁺CD56⁺ (natural killer T) lymphocytes. Int J Cancer 98:864CrossRefPubMed

Bernhard H, Salazer L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML (2002) Vaccination against the HER-2/neu oncogenic protein. Endocrine-Related Cancer 9:33

Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W (1998) HER-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58:732PubMed

10.

Brossart P, Wirths S, Stuhler G, Reichardt UL, Kanz L, Brugger W (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102PubMed

11.

Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285PubMed

12.

Chazin U, Kaleko M, Miller A (1992) Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 7:1859PubMed

13.

Chen PW, Ananthaswamy HN (1993) Rejection of K1735 murine melanoma in syngeneic hosts required expression of MHC class I antigens and either class II antigens of IL-2. J Immunol 151:244PubMed

14.

Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA (1994) Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16PubMed

15.

Disis ML, Grabstein KH, Sleath DR, Cheever MA (1996) Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 5:1289

16.

Disis ML, Cheever MA (1997) HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 71:343PubMed

17.

Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA (1997) High titer HER-2/neu protein specific antibody immunity can be detected in patients with early stage breast cancer. J Clin Oncol 15:3363PubMed

18.

Disis ML, Knutson KL, Shilffmann K, Rinn K, McNeel DG (2000) Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 62:245CrossRefPubMed

19.

Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Shiffmann K (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20:2624CrossRefPubMed

20.

Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90:720PubMed

21.

Falk K, Roetzscke O, Stevanovic S, Jung G, Rammensee HG (1991) Allele-specific motifs revealed by sequencing of self peptides eluted from MHC molecules. Nature 351:290PubMed

22.

Falk K, Roetzscke O, Stevanovic S, Jung G, Rammensee HG (1994) Pool sequencing of natural HLA-DR, DQ and DP ligands reveals detailed peptide motifs, constraints of processing and general rules. Immunogenetics 39:230PubMed

23.

Fedi P, Pierce J, DiFiore PP, & Kraus MH (1994) Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase Cγ GTPase-activating protein, distinguishes ErbB3 signalling from that of other ErbB/EGFR family members. Mol Cell Biol 14:492PubMed

24.

Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109PubMed

25.

Fisk B, Hudson JM, Kavanagh J, Wharton JT, Murray JL, Ioannides CG, Kudelka AP (1997) Existent proliferative response of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res 17:45PubMed

26.

Fleckenstein B, Jung G, Wiesmueller K-H (1999) Quantitative analysis of peptide-MHC-class II interaction. Semin Immunol 11:405CrossRefPubMed

27.

Foy TM, Fanger GR, Hand S, Gerard C, Bruck C, Cheever MA (2002) Designing HER2 vaccines. Semin Oncol 29:53CrossRef

28.

Gosselin EJ, Wardwell K, Gosselin DR, Alter N, Fisher JL, Guyre PM (1992) Enhanced antigen presentation using human Fc-g receptor-specific immunogens. J Immunol 149:3477PubMed

29.

Gritzapis AD, Mamalaki A, Kretsovali A, Papamatheakis J, Belimezi M, Perez SA, Baxevanis CN, Papamichail M (2003) Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells. Br J Cancer 88:1292CrossRefPubMed

30.

Halder T, Pawelec C, Kirkin AF, Zeuthen J, Meyer HE, Li K, Kalbacher H (1997) Novel class II-restricted melanoma antigens. Cancer Res 57:3138

31.

Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L, Kalbacher H (1997) Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res 57:3238PubMed

32.

Haynes NM, Snook MB, Tragani JA, Cerruti L, Jane SM, Smyth MJ, Darcy DK (2001) Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-ζ vs. FcεRI-γ. J Immunol 166:182PubMed

33.

Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA (1995) In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55:3369PubMed

34.

Hynes NE, Stern DF (1994) The Biology of erbB-2/neu/HER-2 and its role in cancer. Biochem Biophys Acta Rev Cancer 1198:165CrossRef

35.

Karynagaren D, Tzahar E, Beerli RR, Chen X, Grans-Porta D, Ratzkin BJ, Seger R, Aymes NE, Yarden Y (1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15:254PubMed

36.

Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E (1998) The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 59:1

37.

Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E (1999) Identification of HLA-A3-restricted cytotoxic T lymphocytes epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 59:431PubMed

38.

Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A (2001) Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 167:787

39.

Kiessling A, Schmitz M, Stevanovic S, Weigle B, Hoelig K, Fuessel M, Fuessel S, Meye A, Worth MP, Rieber ED (2002) Prostate stem cell antigen: identification of immunogenic peptides and assessment of reactive CD8⁺ T cells in prostate cancer patients. Int J Cancer 102:390CrossRefPubMed

40.

Kiessling R, Wel WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K, Seliger B (2002) Cellular immunity to the HER-2/neu protooncogene. Adv Cancer Res 85:101PubMed

41.

Knutson KL, Shiffmann K, Disis ML (2001) Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107:477PubMed

42.

Knutson KL, Shiffmann K,, Cheever MA, Disis ML (2002) Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369–377, results in short-lived peptide-specific immunity. Clin Cancer Res 8:1014

43.

Kobayashi H, Wood M, Song Y, Appelle E, Celis E (2000) Defining promiscuous MHC class II helper T-cell epitopes for HER-2/neu tumor antigen. Cancer Res. 60:52258

44.

Kobayashi H, Lu J, Celis E (2001) Identification of helper T cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res 61:7577PubMed

45.

Koch C, Anderson D, Moran M, Ellis C, Pawson T (1991) SH2 and SH3 domains: elements that control interactions of cytoplasmic signalling proteins. Science 252:668PubMed

46.

Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appellia E, Sekikawa T, Matsumoto Y, Kiessling R (1998) Identification of HER-2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 78:202CrossRefPubMed

47.

Kun L, Adibzadeh M, Halder T, Kalbacher H, Heinzel S, Mueller C, Zeuthen J, Pawelec G (1998) Tumor-specific MHC-class II-rescticted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother 47:32PubMed

48.

Lewis JJ, Janetzki S, Schaed S, Panageas KS, Wang S, Williams L, Meyers M, Butterworth L, Livingston PO, Chapman PB, Houghton AN (2000) Evaluation of CD8⁺ T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosine peptide. Int J Cancer 100:391CrossRef

49.

Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA (1997) Identification of HER-2/neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Hum Immunol 52:109CrossRefPubMed

50.

Majer J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotech 20:70CrossRefPubMed

51.

Mamalaki A, Gritzapis AD, Kretsovali A, Belimezi M, Papamatheakis J, Perez SA, Papamichail M, Baxevanis CN (2003) In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc (epsilon) RI. Cancer Immunol Immunother (in press)

52.

Mannering SI, McKenzie JL, Fearuley DB, Hart DNJ (1997) HLA-DR1-restricted bcr-abl (b3α2)-specific CD4⁺ T lymphocytes respond to dendritic cells pulsed with b3α2 peptide and antigen-presenting cells exposed to b3α2 containing cell lysates. Blood 90:290PubMed

53.

McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, Disis ML (2000) Antibody immunity to prostate cancer-associated antigens can be detected in the serum of patients with prostate cancer. Urology 164:1825

54.

Moritz D, Wels W, Mattern J, Grower B (1994) Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 91:4318PubMed

55.

Murray JL, Przepiorka D, Ioannides C (2000) Clinical trials of HER-2/neu-specific vaccines. Semin Oncol 27:71PubMed

56.

Nair SK, Bockzowski D, Snyder D, Gilboa E (1997) Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 27:589PubMed

57.

Nanda NK, Sercarz EE (1995) Induction of anti-self-immunity to cure cancer. Cell 82:13PubMed

58.

Niederman TMJ, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC (2002) Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA 99:7009CrossRefPubMed

59.

Ohnishi Y, Nakamura H, Yoshimura M, Tokuda Y, Iwasawa M, Ueyama Y, Tamaoki N, Shimamura K (1995) Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody. Br J Cancer 71:969PubMed

60.

Pawson T, Gish D (1992) SH2 and SH3 domains: from structure to function. Cell 71:359PubMed

61.

Peiper M, Goedegebunre PS, Linehan DC, Ganguly E, Douville CC, Eberlein TJ (1997) The HER-2/neu-derived peptide p654–662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Eur J Immunol 27:1115PubMed

62.

Perez SA, Sotiropoulou PA, Sotiriadou NM, Mamalaki A, Gritzapis AD, Echner H, Voelter W, Pawelec G, Papamichail M, Baxevanis CN (2002) HER-2/neu-derived peptide 884–899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4⁺ T cell clones. Cancer Immunol Immunother 50:615PubMed

63.

Pittet MJ, Zippelins A, Speiser DE, Assenmacher M, Guillaume P, Valmori D, Lienard D, Lejeune F, Cerottini J-C, Romero P (2001) Ex vivo IFN-γ secretion by circulating CD8 T lymphocytes: Implications of a novel approach for T cell monitoring in infections and malignant diseases. J Immunol 166:7634PubMed

64.

Rammensee HG, Friede T, Stevanovic S (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41:178PubMed

65.

Reise DM, Slamon DJ (1997) HER-2/neu signal transduction on human breast and ovarian cancer. Stem Cells 15:1

66.

Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be temporal bridge between a CD4⁺ T-helper and a T-killer cell. Nature 393:474PubMed

67.

Roberts MR, Looke KS, Tran A-C, Smith KA, Lin WL, Wang M, Dull TJ, Farson D, Zsebo KM, Finer MH (1998) Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing ζ or γ signaling domains. J Immunol 161:375PubMed

68.

Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R (1999) Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163:1037PubMed

69.

Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K (2001) Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol 31:3261CrossRefPubMed

70.

Schaller G, Bangemann N, Becker C, Buhler H, Opri F, Weitzel, HK (1999) Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein. J Cancer Res Clin Oncol 125:520CrossRefPubMed

71.

Scheibenbogen C, Lee K-H, Stevanovic S, Witzens M, Willhauck M, Waldmann U, Naeher H, Rammensee H-G, Keiholz U (1997) Analysis of the T cell response to tumor and viral peptide antigens by an IFN-γ Elispot assay. Int J Cancer 71:932CrossRefPubMed

72.

Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJM (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480PubMed

73.

Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudfil K (1993) Dominance and crypticity of T-cell antigenic determinants. Ann Rev Immunol 11:729CrossRef

74.

Shak S (1999) Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 26:71PubMed

75.

Shawver LK, Mann E, Elliger SS, Dugger TC, Arteaga CL (1994) Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells. Cancer Res 54:1367PubMed

76.

Shiku H, Wang L, Ikuta Y, Okugawa T, Schmitt M, Gu X, Akiyoshi K, Sunamoto J, Nakamura H (2000) Development of a cancer vaccine: peptides, proteins and DNA. Cancer Chemother Pharmacol 46:s77CrossRefPubMed

77.

Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26:60

78.

Soltoff SP, Cantley LC (1996) p120cbl is a cytoplasmic adapter protein that associates with phosphoinositide 3-kinase in response to epidermal growth factor in PC12 and other cells. J Biol Chem 271:563CrossRefPubMed

79.

Sotiriadou R, Perez SA, Gritzapis AD, Sotiropoulou PA, Echner H, Heinzel S, Mamalaki A, Pawelec G, Voelter W, Baxevanis CN, Papamichail M (2001) Peptide HER2 (776–788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 85:1527CrossRefPubMed

80.

Sotiropoulou PA, Perez SA, Iliopoulou EG, Missitzis I, Voelter W, Echner H, Baxevanis CN, Papamichail M (2003) Cytotoxic T-cell precursor frequencies to HER-2 (369–377) in patients with HER-2/neu-positive epithelial tumors. Br J Cancer 80:1055

81.

Sotiropoulou PA, Perez SA, Voelter W, Echner H, Missitzis I, Tsavaris NB, Papamichail M, Baxevanis CN (2003) Natural CD8⁺ T cell responses against MHC class I epitopes of the HER-2/neu oncoprotein in patients with epithelial tumors. Cancer Immunol Immunother 52:771

82.

Spyridonidis A, Schmidt M, Bernhardt W et al (1998) Purging of mammary carcinoma cells during ex vivo culture of CD34⁺ hematopoietic progenitor cells with recombinant immunotoxins. Blood 91:1820PubMed

83.

Tokuda Y, Ohnishi Y, Shimamura K, Iwasawa M, Yoshimura M, Ueyama Y, Tamaoki N, Tajima T, Mitomi T (1996) In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 73:1362PubMed

84.

Townsend A, Bodmer H (1989) Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7:601PubMed

85.

Tuttle TM, Anderson BW, Thompson WE, Lee JE, Sahin A, Smith TL, Grabstein KH, Wharton T, Ioannides CG, Murray JL (1998) Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer. Clin Cancer Res 4:2015PubMed

86.

Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingermann H-G, Wels W (2002) Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100:1265PubMed

87.

Vidard L, Rock KL, Benacerraf B (1992) Diversity in MHC class II ovalbumin epitopes generated by distinct proteases. J Immunol 149:498PubMed

88.

Walker RE, Bechtel CM, Natarajan V et al (2000) Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96:467PubMed

89.

Wang R-F (1999) Human tumor antigens: implications for cancer vaccine development. J Mol Med 77:640CrossRefPubMed

90.

Wang R-F, Rosenberg SA (1999) Human tumor antigen for cancer vaccine development. Immunol Rev 170:85PubMed

91.

Ward RL, Hawkins N, Coomber D, Disis ML (1999) Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Hum Immunol 60:510CrossRefPubMed

92.

Weijtens MEM, Willemsen RA, Valerio D, Stam K, Bolhuis RLH (1996) Single chain Ig/γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 157:836PubMed

93.

Xu L, Yee JK, Woltt JA, Friedmann T (1989) Factors affecting long-term stability of Moloney murine leukemia virus-based vectors. Virology 171:331

94.

Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61:1CrossRef

95.

Yip YL, Ward RL (2002) Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother 50:569CrossRefPubMed

96.

Yoshimura A, Shiku H, Nakayama E (1993) Rejection of an IA⁺ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4⁺ and CD4^- CD8^- T cell receptor-αβ phenotypes generated in CD8-depleted C57BL/6 mice. J Immunol 150:4900PubMed

97.

Yoshino I, Goedegebuure PS, Peoples GE, Parish AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlin TJ (1994) HER-2/neu-derived peptides are shared antigens among human non-small lung cancer and ovarian cancer. Cancer Res 54:3387PubMed

98.

Zaks TZ, Rosenberg SA (1998) Immunization with a peptide epitope (p369–377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu⁺ tumors. Cancer Res 58:4902PubMed

Title: Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy
Authors: Constantin N. Baxevanis
Panagiota A. Sotiropoulou
Nectaria N. Sotiriadou
Michael Papamichail
Publication date: 01-03-2004
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 3/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-003-0475-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2004

Exosome-based immunotherapy

A primer on cancer immunology and immunotherapy

Natural killer lymphocytes: biology, development, and function

Identification of tumour antigens by serological analysis of cDNA expression cloning

Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning

Identification of tumor antigens and T-cell epitopes, and its clinical application

Keynote webinar | Spotlight on antibody–drug conjugates in cancer